drugset / Trial / NCT01333267

One Week Comparison Study of PTH and PTHrP Infusions

NCT01333267

Phase 1 Withdrawn University of Pittsburgh
Non-randomizedParallel-groupSingle-blind

Summary

This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers. The investigators plan to infuse low doses of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of calcium. These results will be compared to previous studies of Caucasian volunteers.

Timeline

Start
2015-01
Primary completion
2017-07
Completion
2017-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Parathyroid Hormone-related Protein (1-36) Peptide 2 unknown Intravenous
Subject Teriparatide Protein / enzyme biologic 2 unknown Intravenous